Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer patients: high-dose drug combo tested after first treatment fails

NCT ID NCT06652048

Recruiting now Disease control Sponsor: Jialei Wang Source: ClinicalTrials.gov ↗

First seen Nov 21, 2025 · Last updated May 01, 2026 · Updated 19 times

Summary

This study tests two higher doses of the drug furmonertinib, either alone or combined with chemotherapy, in 60 people with advanced EGFR-mutant non-small cell lung cancer whose disease got worse after initial treatment with a similar drug. The goal is to see if these options can control the cancer longer. Participants will be randomly assigned to one of three treatment groups and followed until their cancer progresses or side effects become too severe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan university shanghai cancer center

    RECRUITING

    Shanghai, Shanghai Municipality, 021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER